In the proposed study, we assessed the predictive role of BMI and FG on efficacy and toxicity outcomes in 102 postmenopausal patients with HR + HER2−, metastatic BC treated with everolimus and exemestane at six cancer centers located in the Lazio region, centre Italy. The gene discussed is ERBB2; the disease is cancer.